<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129269">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01686776</url>
  </required_header>
  <id_info>
    <org_study_id>3.00 # amended version 1.1</org_study_id>
    <nct_id>NCT01686776</nct_id>
  </id_info>
  <brief_title>A Prospective Validation Study of Albumin Kinetics With Tracer 123 I-HSA</brief_title>
  <official_title>A Prospective Validation Study in Healthy Volunteers, Patients With Acute Inflammation and Patients Scheduled for Major Abdominal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ake Norberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <authority>Sweden: Medical Products Agency.Amend approved#:151:2012/87317</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, validation study of a extempore made tracer compared with a
      commercial. Studies with tracer have no medical effects but are used for studying human
      physiology, in this case pharmacokinetic variables of endogenous albumin distribution and
      turnover at different levels of inflammation.

        1. Primary Objective:

           - Do the extempore made tracer 123-iodine labeled albumin an commercially manufactured
           SERALB-125 give identical values of calculated blood plasma volume and capillary
           leakage measured as transcapillary escape rate of albumin?

        2. Secondary Objective:

             -  How do three different measures of albumin turnover correlate in volunteers?

             -  How do the pharmacokinetic parameters of endogenous albumin vary between the three
                study groups?
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Transcapillary Escape Rate (TER)of Albumin</measure>
    <time_frame>42 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Is the measured value for 123-I-HSA and 125I-HSA identical/equal regarded TER and plasma volume (PV)?</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fractional catabolic rate (FCR)</measure>
    <time_frame>42 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Non compartmental analysis (NCA) and AUC (time-conc) will be determine the pharmacokinetics like clearance, distribution volume and absolute catabolic rate</description>
  </secondary_outcome>
  <other_outcome>
    <measure>plasma albumin turnover rate</measure>
    <time_frame>42 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>How well does the variables FSR, FCR1, FCR30 correlate? How does the pharmacokinetic parameters differ/varies between the three groups?</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy</condition>
  <condition>SIRS</condition>
  <arm_group>
    <arm_group_label>123 I-HSA + 125 I-HSA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy Volunteers, N=16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>123 I- HSA + 125 I-HSA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients, planned for elective Major Abdominal Surgery, N=16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>123-I-HSA+125 I-HSA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients, with a acute pancreatitis or cholecystitis, N=16</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>123 I-HSA + 125 I HSA</intervention_name>
    <description>Compare and validate the method of measuring albumine turnover rate</description>
    <arm_group_label>123 I-HSA + 125 I-HSA</arm_group_label>
    <arm_group_label>123 I- HSA + 125 I-HSA</arm_group_label>
    <arm_group_label>123-I-HSA+125 I-HSA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers (treatment arm I)

          -  on contraceptive agent and/or contraceptive device

          -  visual peripheral veins

          -  signed informed consent

          -  planned for elective larger interabdominal surgery (treatment arm II)

          -  patients with a acute pancreatitis or cholecystitis (treatment arm III)

        Exclusion Criteria:

          -  pregnant women and/or lactating

          -  allergy towards excipients in 123 I HSA or 125 I HSA

          -  participates in another study involving radiation or stabile isotopes within a period
             of   60 days to study start

          -  it is the opinion of the principle investigator that the patient/subject should not
             participate for his/hers own good
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olav Rooyackers, PhDProfessor</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska University Hopsital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Åke Norbebrg, M.D PhD</last_name>
    <phone>+46-8-58585159</phone>
    <email>ake.norberg@karolinska.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Karolinska University Hospital, Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Åke Norberg, M.D.,PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 16, 2013</lastchanged_date>
  <firstreceived_date>September 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Ake Norberg</investigator_full_name>
    <investigator_title>M.D, PhD</investigator_title>
  </responsible_party>
  <keyword>Plasma albumine</keyword>
  <keyword>Plasma volume</keyword>
  <keyword>Transcapillary escape rate</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Circulation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
